Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency

Hormone and Metabolic Research

Volumn 45, Issue 2, 2013, Pages 96-101

  Langenheim, J ^a   Ventz, M ^a   Hinz, A ^b   Quinkler, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

AddiQoL; Addison's disease; cortisol circadian rhythm; GBB 24; glucocorticoid replacement therapy; MFI

Indexed keywords

FLUDROCORTISONE; LEVOTHYROXINE; PRASTERONE; PREDNISOLONE; PREDNISONE;

ADDISON DISEASE SPECIFI C QUESTIONNAIRE; ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID RELEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FATIGUE; FEMALE; GIESSENER BESCHWERDEBOGEN QUESTIONNAIRE; HUMAN; HYPOTHYROIDISM; MALE; MORNING DOSAGE; MULTIDIMENSIONAL FATIGUE INVENTORY QUESTIONNAIRE; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE;

ADDISON DISEASE; ADRENAL INSUFFICIENCY; AGED; CIRCADIAN RHYTHM; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; GERMANY; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PILOT PROJECTS; PREDNISONE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84874110362     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1316293     Document Type: Article

References (34)

1. Arlt W., Allolio B. Adrenal insufficiency. Lancet: 2003; 361 9372 1881 1893
2. Oelkers W. Adrenal insufficiency. New England Journal of Medicine: 1996; 335 1206 1212
3. Crown A., Lightman S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf): 2005; 63 483 492
4. Quinkler M., Hahner S. What is the best longterm management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf): 2012; 76 21 25
5. Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab: 2009; 94 1059 1067
6. Riedel M., Wiese A., Schurmeyer T. H., Brabant G. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Exp Clin Endocrinol: 1993; 101 106 111
7. Wichers M., Springer W., Bidlingmaier F., Klingmuller D. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clin Endocrinol (Oxf): 1999; 50 759 765
8. Lovas K., Loge J. H., Husebye E. S. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf): 2002; 56 581 588
9. Hahner S., Loeffler M., Fassnacht M., Weismann D., Koschker A. C., Quinkler M., Decker O., Arlt W., Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab: 2007; 92 3912 3922
10. Merza Z., Rostami-Hodjegan A., Memmott A., Doane A., Ibbotson V., Newell-Price J., Tucker G. T., Ross R. J. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf): 2006; 65 45 50
11. Lovas K., Husebye E. S. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol: 2007; 157 109 112
12. Johannsson G., Bergthorsdottir R., Nilsson A. G., Lennernas H., Hedner T., Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol: 2009; 161 119 130
13. Debono M., Ghobadi C., Rostami-Hodjegan A., Huatan H., Campbell M. J., Newell-Price J., Darzy K., Merke D. P., Arlt W., Ross R. J. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab: 2009; 94 1548 1554
14. Buttgereit F., Doering G., Schaeffler A., Witte S., Sierakowski S., Gromnica-Ihle E., Jeka S., Krueger K., Szechinski J., Alten R. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet: 2008; 371 9608 205 214
15. Lovas K., Curran S., Oksnes M., Husebye E. S., Huppert F. A., Chatterjee V. K. Development of a Disease-Specific Quality of Life Questionnaire in Addison's Disease. J Clin Endocrinol Metab: 2010; 95 545 551
16. Oksnes M., Bensing S., Hulting A. L., Kampe O., Hackemann A., Meyer G., Badenhoop K., Betterle C., Parolo A., Giordano R., Falorni A., Papierska L., Jeske W., Kasperlik-Zaluska A. A., Chatterjee V. K., Husebye E. S., Lovas K. Quality of Life in European Patients with Addison's Disease: Validity of the Disease-Specific Questionnaire AddiQoL. J Clin Endocrinol Metab: 2012; 97 568 576
17. Brahler E., Schumacher J., Brahler C. First all-Germany standardization of the brief form of the Gissen Complaints Questionnaire GBB-24. Psychother Psychosom Med Psychol: 2000; 50 14 21
18. Smets E. M., Garssen B., Bonke B., De Haes J. C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res: 1995; 39 315 325
19. Hinz A., Fleischer M., Brahler E., Wirtz H., Bosse-Henck A. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry: 2011; 33 462 468
20. Kuhnt S., Ernst J., Singer S., Ruffer J. U., Kortmann R. D., Stolzenburg J. U., Schwarz R. Fatigue in cancer survivors - prevalence and correlates. Onkologie: 2009; 32 312 317
21. Schwarz R., Krauss O., Hinz A. Fatigue in the general population. Onkologie: 2003; 26 140 144
22. Mah P. M., Jenkins R. C., Rostami-Hodjegan A., Newell-Price J., Doane A., Ibbotson V., Tucker G. T., Ross R. J. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf): 2004; 61 367 375
23. Arlt W., Rosenthal C., Hahner S., Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf): 2006; 64 384 389
24. Groves R. W., Toms G. C., Houghton B. J., Monson J. P. Corticosteroid replacement therapy: twice or thrice daily? J R Soc Med: 1988; 81 514 516
25. Bleicken B., Hahner S., Loeffler M., Ventz M., Decker O., Allolio B., Quinkler M. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf): 2010; 72 297 304
26. Bleicken B., Hahner S., Loeffler M., Ventz M., Allolio B., Quinkler M. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol: 2008; 159 811 817
27. Bleicken B., Hahner S., Ventz M., Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci: 2010; 339 525 531
28. Erichsen M. M., Lovas K., Skinningsrud B., Wolff A. B., Undlien D. E., Svartberg J., Fougner K. J., Berg T. J., Bollerslev J., Mella B., Carlson J. A., Erlich H., Husebye E. S. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab: 2009; 94 4882 4890
29. Johannsson G., Nilsson A. G., Bergthorsdottir R., Burman P., Dahlqvist P., Ekman B., Engstrom B. E., Olsson T., Ragnarsson O., Ryberg M., Wahlberg J., Biller B. M., Monson J. P., Stewart P. M., Lennernas H., Skrtic S. Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation. J Clin Endocrinol Metab: 2012; 97 473 481
30. Grossmann C., Scholz T., Rochel M., Bumke-Vogt C., Oelkers W., Pfeiffer A. F., Diederich S., Bahr V. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol: 2004; 151 397 406
31. Stavreva D. A., Wiench M., John S., Conway-Campbell B. L., McKenna M. A., Pooley J. R., Johnson T. A., Voss T. C., Lightman S. L., Hager G. L. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol: 2009; 11 1093 1102
32. Arlt W., Willis D. S., Wild S. H., Krone N., Doherty E. J., Hahner S., Han T. S., Carroll P. V., Conway G. S., Rees D. A., Stimson R. H., Walker B. R., Connell J. M., Ross R. J. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab: 2010; 95 5110 5121
33. Newell-Price J., Whiteman M., Rostami-Hodjegan A., Darzy K., Shalet S., Tucker G. T., Ross R. J. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf): 2008; 68 130 135
34. Verma S., Van Ryzin C., Sinaii N., Kim M. S., Nieman L. K., Ravindran S., Calis K. A., Arlt W., Ross R. J., Merke D. P. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf): 2010; 72 441 447